The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Katunina E.A.

Department of Neurology, Neurosurgery and Medical Genetics of the Pirogov Russian National Research Medical University of the Ministry of Health of the Russia, Moscow, Russia

Ilina E.P.

N.I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia

Sadekhova G.A.

N.I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia

Gaisenuk E.I.

N.I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia

Approaches to early diagnosis of Parkinson’s disease

Authors:

Katunina E.A., Ilina E.P., Sadekhova G.A., Gaisenuk E.I.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(6): 119‑127

DOI: 10.17116/jnevro2019119061119

Read: 5941 times

Download PDF (RU)
Contact the author
Table of contents

APPROACHES TO EARLY DIAGNOSIS OF PARKINSON’S DISEASE
APPROACHES TO EARLY DIAGNOSIS OF PARKINSON’S DISEASE

To cite this article:

Katunina EA, Ilina EP, Sadekhova GA, Gaisenuk EI. Approaches to early diagnosis of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(6):119‑127. (In Russ.)
https://doi.org/10.17116/jnevro2019119061119

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Pathomorphosis of the Parkinson’s disease against the background of DBS STN. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):21-27
The effect of bila­teral subthalamic nucleus deep brain stimulation on gait and bala­nce in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):94-101
Neuroinflammatory and neurodegenerative aspe­cts of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):102-111
Schi­zophrenic spectrum diso­rders and Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):136-141
Art and creativity in Parkinson’s disease: the mysterious effe­cts of dopa­mine. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):13-20
Correlation of motor symptoms and cardiovascular dysfunction in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):59-67
Diagnoctic test accu­racy of nucleated red blood cells in non-hematologic inte­nsive care patients (meta-analysis). Russian Journal of Anesthesiology and Reanimatology. 2025;(2):68-82
Prognostic significance of NT-proBNP and sST2 in patients with chro­nic heart failure and redu­ced ejection fraction after previous deco­mpensation. Russian Cardiology Bulletin. 2025;(1):49-56
On the path to personalized cardiology: prospects of precise asse­ssment of cardiovascular risks and predictive-prognostic diagnostics. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):206-215
Diagnostic and prognostic pote­ntial of modern biomarkers in community-acquired pneumonia in children. Russian Journal of Preventive Medi­cine. 2025;(4):130-135
Abstract:

Parkinson’s disease (PD) is characterized by a long period of «latent» course of the neurodegenerative process. Non-motor symptoms, including behavioral dysfunction in the REM sleep phase, hyposmia, constipation, depression, may be detected in patients before the development of movement disorders. The combination of these manifestations can be used to identify the risk group for the subsequent development of PD. These patients can be further investigated using biomarkers. Dopamine receptor agonists are the first-choice drugs at the onset of disease, providing correction of not only motor, but also non-motor symptoms.

Keywords:

Parkinson’s disease
early diagnosis
non-motor symptoms
biomarkers
dopamine receptor agonists
pronoran

Authors:

Katunina E.A.

Department of Neurology, Neurosurgery and Medical Genetics of the Pirogov Russian National Research Medical University of the Ministry of Health of the Russia, Moscow, Russia

Ilina E.P.

N.I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia

Sadekhova G.A.

N.I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia

Gaisenuk E.I.

N.I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia

Close metadata

References:

  1. GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990—2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017;16(11):877-897. https://doi.org/10.1016/S1474-4422(17)30299-5
  2. GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990—2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):939-953. https://doi.org/10.1016/S1474-4422(18)30295-3
  3. Rossi A, Berger K, Chen H, Leslie D, Mailman RB, Huang X. Projection of the prevalence of Parkinson’s disease in the coming decades: revisited. Mov Disord. 2018;33(1):156-159. https://doi.org/10.1002/mds.27063
  4. Gardner RC, Byers AL, Barnes DE, Li Y, Boscardin J, Yaffe K. Mild TBI and risk of Parkinson disease: a Chronic Effects of Neurotrauma Consortium study. Neurology. 2018;90(20):1771-1779. https://doi.org/10.1212/WNL.0000000000005522
  5. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G. MDS Clinical Diagnostic Criteria for Parkinson’s Disease. Movement Disorders. 2015;30(12):1591-1599. https://doi.org/10.1002/mds.26424
  6. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197-211. https://doi.org/10.1016/S0197-4580(02)00065-9
  7. Jellinger K. Overview of morphological changes in Parkinson’s disease. Adv Neurol. 1987;45:1-18.
  8. Iwanaga K, Wakabayashi K, Yoshimoto M, Tomita I, Satoh H, Takashima H, Satoh A, Seto M, Tsujihata M, Takahashi H. Lewy body-type degeneration in cardiac plexus in Parkinson’s and incidental Lewy body diseases. Neurology. 1999;52(6):1269-1271. https://doi.org/10.1212/wnl.52.6.1269
  9. Gjerløff T, Fedorova T, Knudsen K, Munk OL, Nahimi A, Jacobsen S, Danielsen EH, Terkelsen AJ, Hansen J, Pavese N, Brooks DJ, Borghammer P. Imaging acetylcholinesterase density in peripheral organs in Parkinson’s disease with 11C-donepezil PET. Brain. 2015;138(3):653-663. https://doi.org/10.1093/brain/awu369
  10. Adler CH, Dugger BN, Hentz JG, Hinni ML, Lott DG, Driver Dunckley E, Mehta S, Serrano G, Sue LI, Duffy A, Intorcia A, Filon J, Pullen J, Walker DG, Beach TG. Peripheral synucleinopathy in early parkinson’s disease: submandibular gland needle biopsy findings. Mov Disord. 2016;31(2):250-256. https://doi.org/10.1002/mds.26476
  11. Gibbons CH, Garcia J, Wang N, Shih LC, Freeman R. The diagnostic discrimination of cutaneous a-synuclein deposition in Parkinson disease. Neurology. 2016;87(5):505-512. https://doi.org/10.1212/WNL.0000000000002919
  12. Wu Y, Le W, Jankovic J. Preclinical Biomarkers of Parkinson Disease. Arch Neurol. 2011;68(1):22-30. https://doi.org/10.1001/archneurol.2010.321
  13. Witt M, Bormann K, Gudziol V, Pehlke K, Barth K, Minovi A, Hähner A, Reichmann H, Hummel T. Biopsies of olfactory epithelium in patients with Parkinson’s disease. Mov Disord. 2009;24(6):906-914. https://doi.org/10.1002/mds.22464
  14. Wattendorf E, Welge-Lüssen A, Fiedler K, Bilecen D, Wolfensberger M, Fuhr P, Hummel T, Westermann B. Olfactory impairment predicts brain atrophy in Parkinson’s disease. Journal of Neuroscience. 2009;29(49):15410-15413. https://doi.org/10.1523/JNEUROSCI.1909-09.2009
  15. Bohnen NI, Müller ML, Kotagal V, Koeppe RA, Kilbourn MA, Albin RL, Frey KA. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson’s disease. Brain. 2010;133(6):1747-1754. https://doi.org/10.1093/brain/awq079
  16. Johansen KK, Warø BJ, Aasly JO. Olfactory dysfunction in sporadic Parkinson’s Disease and LRRK2 carriers. Acta Neurol Scand. 2014;129(5):300-306. https://doi.org/10.1111/ane.12172
  17. Ponsen MM, Stoffers D, Twisk JW, Wolters EC, Berendse HW. Hyposmia and executive dysfunction as predictors of future Parkinson’s disease: a prospective study. Mov Disord. 2009;24(7):1060-1065. https://doi.org/10.1002/mds.22534
  18. Tissingh G, Berendse HW, Bergmans P, DeWaard R, Drukarch B, Stoof JC, Wolters EC. Loss of olfaction in de novo and treated Parkinson’s disease: possible implications for early diagnosis. Mov Disord. 2001;16(1):41-46. https://doi.org/10.1002/1531-8257(200101)16:1<41::aid-mds1017>3.0.co;2-m
  19. Doty RL. Olfactory dysfunction in Parkinson disease. Nat Rev Neurol. 2012;8(6):329-339. https://doi.org/10.1038/nrneurol.2012.80
  20. Savica R, Carlin JM, Grossardt BR, Bower JH, Ahlskog JE, Maraganore DM, Bharucha AE, Rocca WA. Medical records documentation of constipation preceding Parkinson’s disease: A casecontrol study. Neurology. 2009;73(21):1752-1758. https://doi.org/10.1212/WNL.0b013e3181c34af5
  21. Sakakibara R, Uchiyama T, Yamanishi T, Kishi M. Genitourinary dysfunction in Parkinson’s disease. Mov Disord. 2010;25(1):2-12. https://doi.org/10.1002/mds.22519
  22. Liddle RA. Parkinson’s disease from the gut. Brain Res. 2018;1693(B):201-206. https://doi.org/10.1016/j.brainres.2018.01.010
  23. Pan-Montojo F, Schwarz M, Winkler C, Arnhold M, O’Sullivan GA, Pal A, Said J, Marsico G, Verbavatz JM, Rodrigo-Angulo M, Gille G, Funk RH, Reichmann H. Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Rep. 2012;2:898. https://doi.org/10.1038/srep00898
  24. Goldman JG, Postuma R. Premotor and non-motor features of Parkinson’s disease. Curr Opin Neurol. 2014;27(4):434-441. https://doi.org/10.1097/WCO.0000000000000112
  25. Postuma RB, Gagnon JF, Vendette M, Charland K, Montplaisir J. Manifestations of Parkinson disease differ in association with REM sleep behavior disorder. Mov Disord. 2008;23(12):1665-1672. https://doi.org/10.1002/mds.22099
  26. Aarsland D, Brønnick K, Alves G, Tysnes OB, Pedersen KF, Ehrt U, Larsen JP. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2009;80(8):928-930. https://doi.org/10.1136/jnnp.2008.166959
  27. Fang F, Xu Q, Park Y, Huang X, Hollenbeck A, Blair A, Schatzkin A, Kamel F, Chen H. Depression and the subsequent risk of Parkinson’s disease in the NIH-AARP Diet and Health Study. Mov Disord. 2010;25(9):1157-1162. https://doi.org/10.1002/mds.23092
  28. Siepel FJ, Brønnick KS, Booij J, Ravina BM, Lebedev AV, Pereira JB, Grüner R, Aarsland D. Cognitive executive impairment and dopaminergic deficits in de novo Parkinson’s disease. Mov Disord. 2014;29(14):1802-1808. https://doi.org/10.1002/mds.26051
  29. Jennings DL, Seibyl JP, Oakes D, Eberly S, Murphy J, Marek K. (123I) beta-CIT and singlephoton emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol. 2004;61(8):1224-1229. https://doi.org/10.1001/archneur.61.8.1224
  30. Berg D, Behnke S, Seppi K, Godau J, Lerche S, Mahlknecht P, Liepelt-Scarfone I, Pausch C, Schneider N, Gaenslen A, Brockmann K, Srulijes K, Huber H, Wurster I, Stockner H, Kiechl S, Willeit J, Gasperi A, Fassbender K, Gasser T, Poewe W. Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson’s disease. Mov Disord. 2013;28(2):216-219. https://doi.org/10.1002/mds.25192
  31. Berg D, Becker G, Zeiler B, Tucha O, Hofmann E, Preier M, Benz P, Jost W, Reiners K, Lange KW. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology. 1999;53(5):1026-1031. https://doi.org/10.1212/wnl.53.5.1026
  32. De Marzi R, Seppi K, Högl B, Müller C, Scherfler C, Stefani A, Iranzo A, Tolosa E, Santamarìa J, Gizewski E, Schocke M, Skalla E, Kremser C, Poewe W. Loss of dorsolateral nigral hyperintensity on 3.0 tesla susceptibility-weighted imaging in idiopathic rapid eye movement sleep behavior disorder. Ann Neurol. 2016;79(6):1026-1030. https://doi.org/10.1002/ana.24646
  33. Courbon F, Brefel-Courbon C, Thalamas C, Alibelli MJ, Berry I, Montastruc JL, Rascol O, Senard JM. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson’s disease. Mov Disord. 2003;18(8):890-897. https://doi.org/10.1002/mds.10461
  34. Yoshita M. Differentiation of idiopathic Parkinson’s disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci. 1998;155(1):60-67. https://doi.org/10.1016/s0022-510x(97)00278-5
  35. Jacobson AF, Travin MI. Impact of medications on mIBG uptake, with specific attention to the heart: Comprehensive review of the literature. J Nucl Cardiol. 2015;22(5):980-993. https://doi.org/10.1007/s12350-015-0170-z
  36. Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Kang UJ, Cain KC, Wang Y, Aasly J, Goldstein D, Zhang J. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol. 2011;69(3):570-580. https://doi.org/10.1002/ana.22311
  37. Parnetti L, Farotti L, Eusebi P, Chiasserini D, De Carlo C, Giannandrea D, Salvadori N, Lisetti V, Tambasco N, Rossi A, Majbour NK, El-Agnaf O, Calabresi P. Differential role of CSF alphasynuclein species, tau, and Aβ42 in Parkinson’s Disease. Front. Aging Neurosci. 2014;6:53. https://doi.org/10.3389/fnagi.2014.00053
  38. Gao L, Tang H, Nie K, Wang L, Zhao J, Gan R, Huang J, Zhu R, Feng S, Duan Z, Zhang Y, Wang L. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson’s disease diagnosis: a systematic review and meta-analysis. Int J Neurosci. 2015;125(9):645-654. https://doi.org/10.3109/00207454.2014.961454
  39. Chung SJ, Kim J, Lee HJ, Ryu HS, Kim K, Lee JH, Jung KW, Kim MJ, Kim MJ, Kim YJ, Yun SC, Lee JY, Hong SM, Myung SJ. Alpha-synuclein in gastric and colonic mucosa in Parkinson’s disease: Limited role as a biomarker. Mov Disord. 2016;31(2):241-249. https://doi.org/10.1002/mds.26473
  40. Antunes L, Frasquilho S, Ostaszewski M, Weber J, Longhino L, Antony P, Baumuratov A, Buttini M, Shannon KM, Balling R, Diederich NJ. Similar α-Synuclein staining in the colon mucosa in patients with Parkinson’s disease and controls. Mov Disord. 2016;31(10):1567-1570. https://doi.org/10.1002/mds.26702
  41. Wider C, Wszolek ZK. Clinical genetics of Parkinson’s disease and related disorders. Parkinsonism Relat Disord. 2007;13(3):229-232. https://doi.org/10.1016/S1353-8020(08)70007-5
  42. Waragai M, Wei J, Fujita M, Nakai M, Ho GJ, Masliah E, Akatsu H, Yamada T, Hashimoto M. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson’s disease. Biochem Biophys Res Commun. 2006;345(3):967-972. https://doi.org/10.1016/j.bbrc.2006.05.011
  43. Han B, Wang J, Gao J, Feng S, Zhu Y, Li X, Xiao T, Qi J, Cui W. DJ-1 as a potential biomarker for the early diagnosis in lung cancer patients. Tumour Biol. 2017;39(6):1010428317714625. https://doi.org/10.1177/1010428317714625
  44. Dongworth RK, Mukherjee UA, Hall AR, Astin R, Ong SB, Yao Z, Dyson A, Szabadkai G, Davidson SM, Yellon DM, Hausenloy DJ. DJ-1 protects against cell death following acute cardiac ischemia-reperfusion injury. Cell Death Dis. 2014;5:e1082. https://doi.org/10.1038/cddis.2014.41
  45. Gao X, O’Reilly EJ, Schwarzschild MA, Ascherio A. Prospective study of plasma urate and risk of Parkinson disease in men and women. Neurology. 2016;86(6):520-526. https://doi.org/10.1212/WNL.0000000000002351
  46. Antón FM, García Puig J, Ramos T, González P, Ordás J. Sex differences in uric acid metabolism in adults: evidence for a lack of influence of estradiol-17 beta (E2) on the renal handling of urate. Metabolism. 1986;35(4):343-348. https://doi.org/10.1016/0026-0495(86)90152-6
  47. Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin EA, Oakes D, Rudolph A, Shoulson I, Tennis MK, Espay AJ, Gartner M, Hung A, Bwala G, Lenehan R, Encarnacion E, Ainslie M, Castillo R, Togasaki D, Barles G, Friedman JH, Niles L, Carter JH, Murray M, Goetz CG, Jaglin J, Ahmed A, Russell DS, Cotto C, Goudreau JL, Russell D, Parashos SA, Ede P, Saint-Hilaire MH, Thomas CA, James R, Stacy MA, Johnson J, Gauger L, Antonelle de Marcaida J, Thurlow S, Isaacson SH, Carvajal L, Rao J, Cook M, Hope-Porche C, McClurg L, Grasso DL, Logan R, Orme C, Ross T, Brocht AF, Constantinescu R, Sharma S, Venuto C, Weber J, Eaton K. Parkinson Study Group SURE-PD Investigators, Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014;71(2):141-150. https://doi.org/10.1001/jamaneurol.2013.5528
  48. Swanson CR, Berlyand Y, Xie SX, Alcalay RN, Chahine LM, Chen-Plotkin AS. Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson’s disease patients. Mov Disord. 2015;30(12):1648-1656. https://doi.org/10.1002/mds.26290
  49. Qiang JK, Wong YC, Siderowf A, Hurtig HI, Xie SX, Lee VM, Trojanowski JQ, Yearout D, Leverenz BJ, Montine TJ, Stern M, Mendick S, Jennings D, Zabetian C, Marek K, Chen-Plotkin AS. Plasma apolipoprotein A1 as a biomarker for Parkinson disease. Ann Neurol. 2013;74(1):119-127. https://doi.org/10.1002/ana.23872
  50. Millan MJ. From the cell to the clinic: a comparative review of the partial D2/D3receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson’s disease. Pharmacol Ther. 2010;128(2):229-273. https://doi.org/10.1016/j.pharmthera.2010.06.002
  51. Delaville C, Deurwaerdère PD, Benazzouz A. Noradrenaline and Parkinson’s disease. Front Syst Neurosci. 2011;5:31. https://doi.org/10.3389/fnsys.2011.00031
  52. Gobert A, Di Cara B, Cistarelli L, Millan MJ. Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors. J Pharmacol Exp Ther. 2003;305(1):338-346. https://doi.org/10.1124/jpet.102.046383
  53. Calzi F, Bellasio R, Guiso G, Caccia S, Tacconi MT. Effect of piribedil and its metabolite, S584, on brain lipid peroxidation in vitro and in vivo. Eur J Pharmacol. 1997;5(338):185-190. https://doi.org/10.1016/s0014-2999(97)81947-4
  54. Münchau A, Bhatia KP. Pharmacological treatment of Parkinson’s disease. Postgrad Med J. 2000;76(900):602-610. https://doi.org/10.1136/pmj.76.900.602
  55. Rascol O, Dubois B, Caldas AC, Senn S, Del Signore S, Lees A. Early Piribedil Monotherapy of Parkinson’s Disease: A Planned Seven-Month Report of the REGAIN Study. Movement Disorders. 2006;12(21):2110-2115. https://doi.org/10.1002/mds.21122
  56. Rondot P, Ziegler M. Activity and acceptability of piribedil in Parkinson’s disease: a multicentre study. J Neurol. 1992;239:28-34.
  57. Ziegler M, Castro-Caldas A, Del Signore S, Rascol O. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson’s disease: a 6-month, randomized, placebo-controlled study. Mov Disord. 2003;18(4):418-425. https://doi.org/10.1002/mds.10359
  58. Pilipovich AA, Golubev VL. Vliyanie pronorana na kognitivnye i affektivnye narusheniya pri bolezni Parkinsona. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2005;105(4):41-47. (In Russ.)
  59. Ollat H. Dopaminergic insufficiency reflecting cerebral ageing: value of a dopaminergic agonist, piribedil. J Neurol. 1992;239(1):13-16.
  60. Valdés P, Schneider BL. Gene Therapy: A Promising Approach for Neuroprotection in Parkinson’s Disease? Front Neuroanat. 2016;10:123. https://doi.org/10.3389/fnana.2016.00123
  61. Brocco M, Dekeyne A, Papp M, Millan MJ. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors Behav. Pharmacol. 2006;17(7):559-572. https://doi.org/10.1097/01.fbp.0000236267.41806.5b
  62. Pedersen KF, Alves G, Bronnick K, Aarsland D, Tysnes OB, Larsen JP. Apathy in drug-naive patients with incident Parkinson’s disease: the Norwegian ParkWest study. J Neurol. 2010;257(2):217-223. https://doi.org/10.1007/s00415-009-5297-x
  63. Dujardin K, Langlois C, Plomhause L, Carette AS, Delliaux M, Duhamel A, Defebvre L. Apathy in untreated early-stage Parkinson disease: relationship with other non-motor symptoms. Mov Disord. 2014;29(14):1796-1801. https://doi.org/10.1002/mds.26058
  64. Marin RS, Fogel BS, Hawkins J, Duffy J, Krupp B. Apathy: a treatable syndrome. J Neuropsychiatry Clin Neurosci. 1995;7(1):23-30. https://doi.org/10.1176/jnp.7.1.23
  65. Thobois S, Lhommee E, Klinger H, Ardouin C, Schmitt E, Bichon A, Kistner A, Castrioto A, Xie J, Fraix V, Pelissier P, Chabardes S, Mertens P, Quesada JL, Bosson JL, Pollak P, Broussolle E, Krack P. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain. 2013;136(5):1568-1577. https://doi.org/10.1093/brain/awt067
  66. Tracik F, Ebersbach G. Sudden daytime sleep onset in Parkinson’s disease: polysomnographic recordings. Mov Disord. 2001;16(3):500-506. https://doi.org/10.1002/mds.1083
  67. Ulivelli M, Rossi S, Lombardi C. Polysomnographic characterization of pergolide-induced sleep attacks in idiopathic PD. Neurology. 2002;58(3):462-465. https://doi.org/10.1212/wnl.58.3.462
  68. Frucht S, Rogers JD, Grene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinerole. Neurology. 1999;52(9):1908-1910. https://doi.org/10.1212/wnl.52.9.1908
  69. Eggert K, Ohlwein C, Kassubek J, Wolz M, Kupsch A, Ceballos-Baumann A, Ehret R, Polzer U, Klostermann F, Schwarz J, Fuchs G, Jost W, Albert A, Haag A, Hermsen A, Lohmüller K, Kuhn K, Wangemann M, Oertel WH. In Cooperation With the German Competence Network on Parkinson’s Disease. Influence of nonergot dopamine agonist piribedil on vigilance in Parkinson’s disease and excessive daytime sleepiness (pivicog-pd): an 11-week randomized comparison trial against pramipexole and ropinerole. Clincal Neuropharmcol. 2014;37(4):116-122. https://doi.org/10.1097/WNF.0000000000000041
  70. Milan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. Differential actions of antiparkinson agent at multiple classes of monoaminoaminergic receptor. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002;303(2):791-804. https://doi.org/10.1124/jpet.102.039867
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.